Sandra and Edward Meyer Cancer Center

Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research. 

A team led by Weill Cornell Medicine scientists has pioneered a method for manufacturing functioning human blood vessels and demonstrated that they can carry blood in lab-grown model organs and tumors.

A preclinical model of a common type of breast cancer provides new insight into why an immunotherapy known as checkpoint inhibition has not yet been effective against the cancer

The greatly increased risk of cancer and cancer mortality with aging may be due in part to the buildup in the body of a key cancer-promoting molecule, according to new preclinical research from scientists at Weill Cornell Medicine.

Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, has been named a 2020 Vallee Scholar by the Vallee Foundation.

Tiny packets called extracellular vesicles and particles (EVPs), released by cancer and immune cells, contain specific proteins that may serve as reliable biomarkers for diagnosing early-stage cancer, according to investigators at Weill Cornell Medicine and Memorial Sloan Kettering.

A new set of laboratory models designed to study variations in one of the most commonly mutated genes in cancer has revealed that each variation has a different effect on the colon and pancreas, according to investigators at Weill Cornell Medicine. The models also provide a new platform for screening potential therapies.

Localized radiation therapy against a tumor can trigger a beneficial immune response throughout the body by releasing DNA from mitochondria into the cytoplasm of tumor cells, according to new preclinical research by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Weill Cornell Medicine and NewYork-Presbyterian have realigned the Department of Healthcare Policy and Research to address the intersection of research and practice. The newly named Department of Population Health Sciences, led by distinguished health services researcher, information scientist and leader Dr. Rainu Kaushal, aims to improve the health of populations through data-driven research, innovative technology and novel education programs.

A code discovered in DNA packaging proteins enables the rapid expression of genes needed to fight immediate threats, a finding that may pave the way for new treatments for cancer and inflammatory diseases.

Two distinguished Weill Cornell Medicine physician-scientists have been elected to the prestigious Association of American Physicians (AAP). 

A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).

A drug that blocks a male hormone receptor prolonged life by nearly a year compared with the placebo in men with nonmetastatic, castration-resistant prostate cancer, according to the final analysis of the results of an international, multi-center Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Gene mutations that are thought to be very early events in the development of leukemias and other blood disorders appear to set the stage for malignancy by increasing the production of certain types of blood cells at the expense of others.

Preclinical work suggests the targeted drug palbociclib may boost the effectiveness of chemotherapy in pancreatic cancer if the two treatments are given in the right sequence.

The scope of the DNA changes that drive cancers has been illuminated as never before in a set of studies by a large international scientific team including Weill Cornell Medicine researchers. In six studies published Feb. 5 in Nature, and 18 papers in other Nature-affiliated journals, this scientific consortium reported the results from analyses of DNA from more than 2,600 biopsied tumor samples across 38 different types of cancer. 

Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them.

A change in the protein composition of chromatin—the condensed, packaged form of DNA in the nucleus—boosts the expression of metastasis-related genes; blocking this change appears to stop tumor cells from forming new tumors in mice, suggests a study by Weill Cornell Medicine investigators.